Liu Yu, Yuan Wei, Fang Miao, Guo Hongying, Zhang Xin, Mei Xue, Zhang Yuyi, Ji Longshan, Gao Yating, Wang Jiefei, Qian Zhiping, Li Man, Gao Yueqiu
Laboratory of Cellular Immunity, Institute of Clinical Immunology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Front Pharmacol. 2023 Jan 13;13:1031790. doi: 10.3389/fphar.2022.1031790. eCollection 2022.
Acute kidney injury (AKI) is a frequent complication in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) and is associated with high rates of mortality. We aimed to estimate serum high mobility group protein 1 (HMGB1) levels in hepatitis B virus-related acute-on-chronic liver failure patients and analyze their clinical value in the development and outcomes of Acute kidney injury. A total of 251 consecutive patients with hepatitis B virus-related acute-on-chronic liver failure were enrolled in this retrospective study. Using the International Club of Ascites staging criteria of Acute kidney injury, 153 patients developed Acute kidney injury. The clinical data of patients were collected and serum levels of high mobility group protein 1 were measured by ELISA. All patients were followed up until death or for a minimum of 3 months. Early prediction and prognostic implications of high mobility group protein 1 in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Patients with Acute Kidney Injury were investigated in different cohorts, including a propensity score-matched ACLF cohort. Among all individuals with hepatitis B virus-related acute-on-chronic liver failure, the incidence of Acute kidney injury was 61.0% (153/251). The patients who developed stage 2/3 Acute kidney injury showed the highest high mobility group protein 1 levels, followed by those who developed stage 1 Acute kidney injury, and those without Acute kidney injury showed the lowest high mobility group protein 1 levels. Moreover, high mobility group protein 1 levels were significantly higher in non-survivors than in survivors among hepatitis B virus-related acute-on-chronic liver failure patients with Acute kidney injury. Furthermore, analysis of the area under the receiver operating characteristic curve (AUROC) indicated that serum high mobility group protein 1 levels (pre-matching: AUC = 0.740; post-matching: AUC = 0.661) may be a potential predictive factor for Acute kidney injury development and that high mobility group protein 1 (AUC = 0.727) might be a reliable biomarker for prognosis in patients with Acute kidney injury. In patients with hepatitis B virus-related acute-on-chronic liver failure, Acute kidney injury is universal. Acute kidney injury and its stages negatively influence the 90-day transplant-free mortality rate. Serum high mobility group protein 1 levels can serve as a positive predictor of Acute kidney injury development, and high mobility group protein 1 might also be a prognostic biomarker for Acute kidney injury among hepatitis B virus-related acute-on-chronic liver failure patients.
急性肾损伤(AKI)是乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者常见的并发症,且与高死亡率相关。我们旨在评估乙型肝炎病毒相关慢加急性肝衰竭患者血清高迁移率族蛋白1(HMGB1)水平,并分析其在急性肾损伤发生及预后中的临床价值。本回顾性研究共纳入251例连续的乙型肝炎病毒相关慢加急性肝衰竭患者。根据国际腹水俱乐部急性肾损伤分期标准,153例患者发生了急性肾损伤。收集患者的临床资料,并采用酶联免疫吸附测定法检测血清高迁移率族蛋白1水平。所有患者均随访至死亡或至少3个月。在不同队列中,包括倾向评分匹配的ACLF队列,研究了高迁移率族蛋白1在乙型肝炎病毒相关慢加急性肝衰竭合并急性肾损伤患者中的早期预测及预后意义。在所有乙型肝炎病毒相关慢加急性肝衰竭患者中,急性肾损伤的发生率为61.0%(153/251)。发生2/3期急性肾损伤的患者高迁移率族蛋白1水平最高,其次是发生1期急性肾损伤的患者,未发生急性肾损伤的患者高迁移率族蛋白1水平最低。此外,在乙型肝炎病毒相关慢加急性肝衰竭合并急性肾损伤的患者中,非存活者的高迁移率族蛋白1水平显著高于存活者。此外,对受试者工作特征曲线下面积(AUROC)的分析表明,血清高迁移率族蛋白1水平(匹配前:AUC = 0.740;匹配后:AUC = 0.66)可能是急性肾损伤发生的潜在预测因素,高迁移率族蛋白1(AUC = 0.727)可能是急性肾损伤患者预后的可靠生物标志物。在乙型肝炎病毒相关慢加急性肝衰竭患者中,急性肾损伤很普遍。急性肾损伤及其分期对90天无移植死亡率有负面影响。血清高迁移率族蛋白1水平可作为急性肾损伤发生的阳性预测指标,高迁移率族蛋白1也可能是乙型肝炎病毒相关慢加急性肝衰竭患者急性肾损伤的预后生物标志物。